FDA authorizes blood purification device to treat COVID-19

The Food and Drug Administration today issued an emergency use authorization for a pair of blood purification systems to treat adult COVID-19 patients admitted to the intensive care unit with severe respiratory illness. The authorized devices filter patients’ blood to remove excess proteins that can cause respiratory or organ failure. The EUA applies to Terumo BCT Inc.’s Spectra Optia Apheresis System and Marker Therapeutics AG’s Depuro D2000 Adsorption Cartridge
Related News Articles
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…